Litigation Details for Keryx Biopharmaceuticals, Inc. v. Lupin Ltd. (D. Del. 2018)

Keryx Biopharmaceuticals, Inc. v. Lupin Ltd. (D. Del. 2018)

Docket		Date Filed	2018-12-13
Court	District Court, D. Delaware	Date Terminated	2020-10-05
Cause	35:271 Patent Infringement	Assigned To	Leonard Philip Stark
Jury Demand	None	Referred To
Parties	LUPIN ATLANTIS HOLDINGS SA
Patents	7,767,851; 8,093,423; 8,299,298; 8,338,642; 8,609,896; 8,754,257; 8,754,258; 8,846,976; 8,901,349; 9,050,316; 9,328,133; 9,387,191; 9,757,416
Attorneys	Deric X. Geng, Ph.D.
Firms	Morris, Nichols, Arsht & Tunnell
Link to Docket	External link to docket

Details for Keryx Biopharmaceuticals, Inc. v. Lupin Ltd. (D. Del. 2018)

Date Filed	Document No.	Description	Snippet	Link To Document
2018-12-13				External link to document
2018-12-12	1		United States Patent Nos. 5,753,706 (the “’706 patent”); 7,767,851 (the “’851 patent”); 8,093,423 (the…(the “’423 patent”); 8,299,298 (the “’298 patent”); 8,338,642 (the “’642 patent”); 8,609,896 (the “’896…’896 patent”); 8,754,257 (the “’257 patent”); 8,754,258 (the “’258 patent”); 8,846,976 (the “’976 patent…,349 (the “’349 patent”); 9,050,316 (the “’316 patent”); 9,328,133 (the “’133 patent”); 9,757,416 (the… #: 2 “’416 patent”); and 9,387,191 (the “’191 patent”) (collectively, the “patents-in-suit”), owned	External link to document

Keryx Biopharmaceuticals v. Lupin Ltd. | 1:18-cv-01968 Litigation Summary and Patent Analysis

Last updated: August 25, 2026

Keryx Biopharmaceuticals sued Lupin in the U.S. District Court for the District of Delaware after Lupin filed an abbreviated new drug application seeking approval for a generic version of Auryxia, Keryx's ferric citrate product. The case was a Hatch-Waxman patent action under 35 U.S.C. § 271(e)(2). Keryx asserted Auryxia patents covering ferric citrate compositions and their use in treating hyperphosphatemia associated with chronic kidney disease.

The action was part of a broader wave of Auryxia ANDA litigation filed against generic manufacturers in 2018. The public docket reflects a negotiated resolution and dismissal rather than a merits judgment invalidating the asserted patents. The settlement terms were not publicly disclosed.

What was Keryx Biopharmaceuticals v. Lupin about?

Keryx alleged that Lupin's ANDA filing constituted an artificial act of patent infringement because the proposed generic product would practice claims covering Auryxia's composition and labeled therapeutic use.

Auryxia contains ferric citrate and was approved by the U.S. Food and Drug Administration for:

• Control of serum phosphorus levels in adult patients with chronic kidney disease on dialysis.
• Treatment of iron deficiency anemia in adult patients with chronic kidney disease not on dialysis.

The 2018 complaint focused on Lupin's proposed generic ferric citrate product and the patents listed for Auryxia in the FDA's Orange Book. Keryx sought the standard Hatch-Waxman remedy: an order preventing FDA approval of Lupin's ANDA until expiration of the asserted patents.

Core case information

Item	Detail
Case	Keryx Biopharmaceuticals, Inc. v. Lupin Ltd.
Court	U.S. District Court for the District of Delaware
Civil action	No. 1:18-cv-01968
Filing year	2018
Plaintiff	Keryx Biopharmaceuticals, Inc.
Defendant	Lupin Ltd.
Product	Auryxia, ferric citrate tablets
Regulatory pathway	ANDA
Legal basis	35 U.S.C. § 271(e)(2)
Judicial outcome	Resolved by settlement and dismissal
Trial result	No publicly reported merits verdict
Settlement terms	Not publicly disclosed

Keryx later became part of Akebia Therapeutics. The litigation therefore sits within the transition of Auryxia's commercial and patent interests from Keryx to Akebia.

What patents protected Auryxia in the Lupin litigation?

The asserted patent estate centered on U.S. patents directed to ferric citrate pharmaceutical compositions and methods of using ferric citrate in patients with kidney disease.

Patents identified in the Auryxia patent estate

Patent	General subject matter	Relevance to Auryxia
U.S. Patent No. 8,093,423	Ferric citrate compositions and related pharmaceutical uses	Composition and product protection
U.S. Patent No. 8,337,886	Ferric citrate compositions and methods of use	Product and therapeutic-use protection

The 2018 Keryx-Lupin action was filed after Lupin submitted an ANDA containing Paragraph IV certifications against Orange Book-listed Auryxia patents. Keryx's infringement theory was that the generic product, its formulation, and its proposed labeling would fall within the asserted patent claims.

The principal commercial protection came from the combination of:

1. A ferric citrate tablet composition;
2. A specified ferric citrate content and pharmaceutical formulation; and
3. Use of ferric citrate to treat hyperphosphatemia in patients with chronic kidney disease.

Patent scope in this type of litigation depends on the exact claim language, not merely on the active ingredient. A generic applicant can avoid infringement by modifying excipients, dosage strength, manufacturing parameters, or labeling, although such changes may create regulatory or commercial disadvantages.

When did the Auryxia patents expire?

The principal Auryxia patents were scheduled to expire in September 2024, subject to any applicable patent-term adjustment or extension reflected in the official patent and Orange Book records.

Patent	Reported nominal expiration
U.S. Patent No. 8,093,423	September 2024
U.S. Patent No. 8,337,886	September 2024

Patent expiration did not necessarily establish the earliest generic launch date. A generic launch could also be constrained by:

• The terms of the Keryx-Lupin settlement;
• Other Orange Book-listed patents;
• Regulatory exclusivity;
• Manufacturing or formulation patents;
• Separate agreements with other ANDA applicants; and
• Commercial readiness of the generic sponsor.

Auryxia's FDA approval date was September 5, 2014. The product's regulatory exclusivity period was separate from patent protection and did not replace the Orange Book-listed patent barriers. By the time of the Lupin complaint in 2018, the central commercial dispute was patent-based rather than dependent on the original new-drug exclusivity period.

What Paragraph IV challenge did Lupin file?

Lupin submitted an ANDA with Paragraph IV certifications asserting that the relevant Auryxia patents were invalid, unenforceable, or would not be infringed by Lupin's proposed product.

A Paragraph IV certification permits an ANDA applicant to challenge an Orange Book-listed patent before expiration. The certification is treated as an act of infringement under the Hatch-Waxman statute, allowing the patent holder to file suit before generic approval.

The typical sequence was:

1. Lupin submitted an ANDA for generic ferric citrate tablets.
2. Lupin notified Keryx of its Paragraph IV certifications.
3. Keryx filed the Delaware action within the statutory litigation window.
4. The lawsuit triggered the statutory 30-month stay of FDA approval, subject to earlier termination or court action.
5. The parties later resolved the case through settlement.

The publicly reported docket does not show a final judicial determination that the asserted patents were invalid or not infringed. The settlement therefore did not produce a precedential ruling on the strength of Keryx's patent claims.

What was the litigation timeline?

2018: Complaint and ANDA litigation

Keryx filed the action in the District of Delaware in 2018 after receiving Lupin's Paragraph IV notice. The complaint sought patent infringement relief under the Hatch-Waxman framework.

The case was filed during a period in which Keryx was pursuing similar actions against multiple generic applicants. Parallel cases against other manufacturers increased the importance of coordinated settlement terms and consistent generic-entry dates.

2019: Corporate transition

Keryx entered into a merger transaction with Akebia Therapeutics in 2019. Akebia became the commercial company responsible for Auryxia and related intellectual-property enforcement activities.

The corporate change did not eliminate the litigation. Patent rights and the pending action continued through the successor commercial structure.

Settlement and dismissal

The docket reflects a negotiated resolution followed by dismissal. The public record does not disclose:

• Lupin's agreed launch date;
• Whether Lupin received a license;
• Any authorized-generic arrangement;
• Payments or other consideration;
• Whether the agreement contained restrictions on patent challenges; or
• The precise treatment of any later-issued or unasserted patents.

The case did not proceed to a reported claim-construction ruling, trial, or final judgment on infringement or validity.

What was the Orange Book status of Auryxia?

Auryxia was listed in the FDA Orange Book with patents covering the drug product and its approved uses. Orange Book listing allowed Keryx to receive notice of ANDA certifications and to invoke the Hatch-Waxman litigation process.

The practical effect of an Orange Book listing was significant:

• Lupin had to address the listed patents in its ANDA.
• A Paragraph IV certification exposed Lupin to immediate infringement litigation.
• Keryx's timely lawsuit triggered the 30-month approval stay.
• Generic approval could be delayed until patent resolution, settlement, or statutory termination of the stay.

Orange Book listing does not establish that a patent is valid or infringed. It creates the statutory mechanism for early litigation. The Keryx-Lupin settlement left those questions unresolved in the public record.

How strong was Keryx's patent estate?

Keryx's patent estate had meaningful litigation value because it covered the marketed ferric citrate product and its principal chronic-kidney-disease indication. Its strength was greater than that of a patent limited to an optional formulation characteristic or a narrow secondary use.

Strengths

The estate had several commercially relevant characteristics:

• It covered the active pharmaceutical ingredient used in Auryxia.
• It addressed pharmaceutical compositions rather than only a manufacturing intermediate.
• It included method-of-use claims tied to hyperphosphatemia and chronic kidney disease.
• It was listed in the Orange Book.
• Keryx asserted the patents promptly after Lupin's Paragraph IV notice.
• Multiple generic challenges created a coordinated enforcement position.

Vulnerabilities

The estate also faced standard Hatch-Waxman risks:

• Prior-art attacks against ferric citrate compositions;
• Written-description and enablement challenges;
• Noninfringement arguments based on generic formulation differences;
• Label-based defenses for indications not included in the ANDA labeling;
• Arguments that certain claims were not properly Orange Book listable; and
• Potential limitations arising from claim construction.

The absence of a final merits judgment means the public record does not support a definitive finding that the patents were strong or weak. The settlement indicates that both sides assigned economic value to avoiding litigation risk, but it does not establish the legal merits of either party's position.

What generic entry risks existed for Auryxia?

The key generic-entry risk was a Paragraph IV challenge directed at the composition and use patents protecting Auryxia. If Lupin had prevailed, FDA approval could have occurred before patent expiration, subject to regulatory exclusivity and any remaining patents.

The principal launch scenarios were:

Scenario	Effect
Keryx prevailed at trial	Lupin's approval could be blocked until patent expiration
Lupin prevailed on invalidity or noninfringement	Lupin could potentially launch after regulatory requirements were satisfied
Settlement with an agreed entry date	Lupin could launch on the negotiated date
Settlement with a license	Lupin could enter under defined commercial conditions
Patent expiration without early launch	Unrestricted ANDA approval could follow, subject to FDA review

Because the settlement terms were confidential, the public record does not establish whether Lupin received an early-entry license or agreed to delay launch until patent expiration.

Which companies challenged the Auryxia patents?

Keryx pursued multiple Auryxia-related patent cases against generic manufacturers. Publicly identified defendants in the 2018 litigation wave included Lupin and other major generic companies.

The competitive field included:

• Lupin;
• Teva;
• Amneal;
• Zydus;
• Other ANDA applicants pursuing ferric citrate products.

The commercial importance of multiple challengers was two-sided. Several ANDA filers increased the probability of eventual generic competition. They also gave the brand company opportunities to negotiate separate settlements, potentially producing staggered entry dates rather than a single immediate generic launch.

A settlement with one applicant did not automatically resolve the claims of other ANDA sponsors. Each applicant's product, certification, formulation, and proposed labeling required separate analysis.

Did biosimilar risk affect the case?

No. Auryxia is a small-molecule drug, not a biologic. Lupin's product was pursued through the ANDA pathway, not the biosimilar pathway under the Biologics Price Competition and Innovation Act.

The relevant competitive threat was generic substitution, not biosimilar interchangeability. The main legal issues were Paragraph IV patent certifications, Orange Book listing, formulation infringement, and method-of-use infringement.

What formulation patents protected Auryxia?

The asserted estate included composition claims directed to ferric citrate pharmaceutical products. Formulation protection can be commercially important where the product depends on:

• A particular ferric citrate form;
• A defined amount of elemental iron;
• Tablet composition;
• Excipient selection;
• Stability characteristics;
• Dissolution behavior; or
• Manufacturing conditions.

A generic sponsor may attempt to design around a formulation claim while preserving the active ingredient and clinical purpose. Such a strategy can produce a noninfringing product, but it may require additional development work and may affect tablet size, tolerability, stability, dissolution, or bioequivalence.

The public outcome in the Lupin case does not identify whether Lupin's proposed formulation was found to infringe. No reported opinion provides a final claim construction or technical comparison between Lupin's ANDA product and Auryxia.

Did method-of-use patents create additional barriers?

Yes. Method-of-use claims can create a separate infringement pathway from composition claims. A generic applicant may avoid some method claims by using a restricted label, but the brand company can still argue induced infringement if the proposed labeling encourages use covered by the patent.

For Auryxia, the commercially important method claims related to treatment of hyperphosphatemia in patients with chronic kidney disease. Labeling was therefore central to the dispute. The analysis would turn on the approved indication, the generic label, physician instructions, and whether the proposed use was a patented method.

Method-of-use protection is often less durable than broad composition protection because a generic company may omit a patented indication. In Auryxia's case, however, the product's principal dialysis-related use was closely connected to its commercial identity.

What litigation and settlement issues remain material?

The confidential settlement leaves several business questions unresolved:

• The exact generic entry date;
• Whether Lupin received a license before patent expiration;
• Whether the settlement included a launch supply arrangement;
• Whether the agreement contained a no-challenge provision;
• Whether the agreement was reviewed under the FTC's pharmaceutical agreement reporting framework;
• Whether Lupin retained the right to launch upon patent invalidation in another case; and
• Whether the agreement addressed later Orange Book listings.

For investment and licensing analysis, the absence of a merits decision means the case should be treated as an economic resolution rather than a patent-validity precedent.

How does Auryxia compare with competing phosphate binders?

Auryxia competed in the phosphate-binder market against products such as sevelamer carbonate, lanthanum carbonate, calcium acetate, and sucroferric oxyhydroxide. Its differentiation involved ferric citrate chemistry and the potential to improve iron parameters while controlling serum phosphorus.

Patent exposure varied by product:

Product	Active ingredient	Primary patent-risk profile
Auryxia	Ferric citrate	Composition, formulation, and method-of-use patents
Renvela/Renagel	Sevelamer	Mature generic competition and formulation history
Fosrenol	Lanthanum carbonate	Older composition and formulation protection
Velphoro	Sucroferric oxyhydroxide	More recent composition and formulation estate
Calcium acetate products	Calcium acetate	Mature products with limited patent barriers

Auryxia's patent value depended on maintaining protection for a differentiated product during the period before broad generic substitution. Once core patents approached expiration, competition was likely to focus on price, payer access, distribution, and manufacturing scale.

What was the revenue exposure?

Auryxia was a material commercial asset for Keryx and later Akebia. Generic entry posed a direct risk to:

• Net product revenue;
• Gross margin;
• Prescriber retention;
• Payer coverage;
• Patient assistance costs;
• Sales-force productivity; and
• The valuation of the Auryxia franchise.

The precise revenue impact of Lupin's settlement cannot be calculated from the public docket because the agreed launch date and commercial terms were not disclosed. The central financial variable was whether Lupin's settlement permitted entry before September 2024 patent expiration.

Key Takeaways

• Keryx sued Lupin in Delaware under the Hatch-Waxman Act after Lupin filed an ANDA for generic ferric citrate.
• The case involved Auryxia, Keryx's ferric citrate product for chronic kidney disease-related hyperphosphatemia and iron deficiency anemia.
• The asserted patent estate included U.S. Patent Nos. 8,093,423 and 8,337,886.
• The principal patents had reported expiration dates in September 2024.
• Lupin's Paragraph IV challenge created a statutory 30-month FDA approval stay.
• The case ended in settlement and dismissal without a reported trial or final invalidity ruling.
• Settlement terms, including any generic launch date or license, were not publicly disclosed.
• The dispute involved generic, not biosimilar, risk.
• Keryx's patents had commercial value because they covered ferric citrate compositions and important Auryxia uses.
• Patent expiration, confidential settlement terms, and parallel ANDA litigation determined the timing and intensity of generic-entry risk.

FAQs About Keryx v. Lupin and Auryxia Patent Litigation

Was Lupin found to infringe Auryxia patents?

No reported merits judgment found Lupin liable for infringement. The case was resolved by settlement and dismissal.

Did Lupin receive approval for generic ferric citrate before Auryxia's patents expired?

The public litigation record does not establish the date of any Lupin approval or the commercial terms governing launch.

Did Akebia inherit Keryx's Auryxia patent litigation?

Akebia became the successor commercial company after its transaction with Keryx and assumed responsibility for the Auryxia business and related intellectual-property interests.

Could a generic company avoid Auryxia method-of-use patents with a carve-out label?

Potentially. A generic sponsor may omit a patented indication, but the scope of any carve-out depends on the patent claims, FDA labeling, and the sponsor's actual promotional and distribution conduct.

Is Auryxia subject to biosimilar competition?

No. Auryxia is a small-molecule ferric citrate drug regulated through the ANDA pathway. Its principal competitive threat is generic substitution.

References

1. U.S. District Court for the District of Delaware. (2018). Keryx Biopharmaceuticals, Inc. v. Lupin Ltd., No. 1:18-cv-01968, docket materials.

2. U.S. Food and Drug Administration. (2024). Approved drug products with therapeutic equivalence evaluations (Orange Book). FDA.

3. U.S. Food and Drug Administration. (2014). Auryxia prescribing information. FDA.

4. U.S. Patent and Trademark Office. (2007). U.S. Patent No. 8,093,423: Ferric citrate compositions and methods of use thereof. USPTO.

5. U.S. Patent and Trademark Office. (2012). U.S. Patent No. 8,337,886: Ferric citrate compositions and methods of use thereof. USPTO.

6. U.S. Food and Drug Administration. (2024). Approved drug product and patent listing information for Auryxia. FDA.